Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528112 | 0.90 | TLR8 (0.77) | TLR8TLR7 | |
| SCHEMBL5146563 | 0.86 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL1527827 | 0.86 | TLR8 (0.70) | TLR8TLR7 | |
| SCHEMBL2400748 | 0.85 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL1528150 | 0.85 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL1528096 | 0.85 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL5146603 | 0.84 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL5144810 | 0.84 | TLR7 (0.50) | TLR8TLR7 | |
| SCHEMBL1528031 | 0.82 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL5146432 | 0.82 | TLR8 (0.55) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793613-B1 | IMMUNOCONJUGATES | BOLT BIOTHERAPEUTICS INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20210154316-A1 | Immunoconjugates | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3793613-A1 | IMMUNOCONJUGATES | Bolt Biotherapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-112153988-A | Immunoconjugates | 博尔特生物治疗药物有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| WO-2006093514-A2 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154316-A1 | Immunoconjugates | FCGR3B, FCGR2A, FCGR1A | TLR8 54/4885TLR7 105/4885 |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | TLR8 86/4885TLR7 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.